Open AccessBiodistribution of Neocarzinostatin Conjugated to Chimeric Fab Fragments of the Monoclonal Antibody A7 in Nude Mice Bearing Human Pancreatic Cancer Xenografts
Author(s) -
Otsuji Eigo,
Yamaguchi Toshiharu,
Yamaoka Nobuki,
Taniguchi Katsunori,
Kato Makoto,
Kotani Tatsuya,
Kitamura Kazuya,
Takahashi Toshio
Publication year - 1994
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1994.tb02391.x
Subject(s) - neocarzinostatin , monoclonal antibody , biodistribution , pancreatic cancer , antibody , cancer research , chemistry , immunoconjugate , conjugated system , microbiology and biotechnology , immunotoxin , pancreatic tumor , cancer , medicine , biology , immunology , dna , biochemistry , in vitro , organic chemistry , polymer
In this study, we conjugated chimeric Fab fragments of the monoclonal antibody (MAb) A7, which reacts with pancreatic cancers, to the antitumor drug neocarzinostatin (chA7Fab‐NCS) and intravenously injected 125 I‐labeled chA7Fab‐NCS into nude mice bearing a human pancreatic cancer xenograft. We compared the tumor localization of 125 I‐labeled chA7Fab‐NCS with that of conventional 125 I‐labeled A7‐NCS, which was produced by conjugation of MAb A7 and NCS. 125 I‐Labeled chA7Fab‐NCS accumulated in the tumor earlier than 125 I‐labeled A7‐NCS, and significantly larger amounts of 125 I‐labeled chA7Fab‐NCS had accumulated in the tumor 1 hour after injection. The results suggest that chA7Fab may be a suitable carrier for NCS in immunotargeting therapy against pancreatic cancer.